Haemonetics (HAE) Common Equity (2010 - 2026)

Haemonetics has reported Common Equity for 17 years, with the latest figure at $796.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 2.99% year-over-year to $796.3 million; the trailing twelve-month figure through Mar 2026 stood at $796.3 million (down 2.99% YoY), and the FY2026 full-year result was $796.3 million, down 2.99% from the prior year.
• Common Equity for Q1 2026 stood at $796.3 million, down from $911.5 million in the prior quarter.
• The five-year high for Common Equity was $960.0 million in Q1 2024, with the low at $729.0 million in Q4 2022.
• Average Common Equity over 5 years is $843.7 million, with a median of $856.9 million recorded in 2023.
• Year-over-year, Common Equity climbed 22.59% in 2023 and declined 14.49% in 2025.
• Tracing HAE's Common Equity over 5 years: stood at $776.0 million in 2022, then climbed by 21.57% to $943.3 million in 2023, then dropped by 3.86% to $906.9 million in 2024, then gained by 0.51% to $911.5 million in 2025, then retreated by 12.63% to $796.3 million in 2026.
• The last three Common Equity figures came in at $796.3 million (Q1 2026), $911.5 million (Q4 2025), and $849.2 million (Q3 2025), per Business Quant data.

Peer Comparison